Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and SNDX-6352 in Intrahepatic Cholangiocarcinoma
NCT04301778Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2021; status: completed.
02
Drugs
axatilimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04301778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301778.